Equities Analysts Issue Forecasts for Indivior Plc’s FY2019 Earnings (INVVY)

Indivior Plc (OTCMKTS:INVVY) – Stock analysts at Jefferies Group upped their FY2019 EPS estimates for Indivior in a research note issued on Wednesday. Jefferies Group analyst J. Vane-Tempest now forecasts that the company will post earnings of $1.10 per share for the year, up from their prior estimate of $1.05. Jefferies Group also issued estimates for Indivior’s FY2021 earnings at $1.65 EPS and FY2022 earnings at $2.40 EPS.

Several other brokerages have also issued reports on INVVY. Zacks Investment Research lowered shares of Indivior from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. ValuEngine upgraded shares of Indivior from a “hold” rating to a “buy” rating in a report on Wednesday, November 29th.

Shares of Indivior (OTCMKTS:INVVY) traded down $0.33 on Thursday, reaching $27.44. 4,282 shares of the company traded hands, compared to its average volume of 7,803. The stock has a market cap of $4,023.12, a price-to-earnings ratio of 109.76, a P/E/G ratio of 2.82 and a beta of 1.13. Indivior has a 12-month low of $17.50 and a 12-month high of $28.40.

ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/18/equities-analysts-issue-forecasts-for-indivior-plcs-fy2019-earnings-invvy.html.

About Indivior

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia.

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit